Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

Akeso’s new drug application for gumokimab, an IL-17-targeting antibody for plaque psoriasis, has been accepted in China.

Eisai and Biogen have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing ...

Obesity-focused Aardvark Therapeutics is hoping to raise $100 million in an initial public offering (IPO), according to a US ...

The US Department of Justice announced Friday that Pfizer has agreed in New York federal court to pay $59.7 million to ...

Swarm Oncology, a biotech developing novel T cell therapies to achieve long-term remission in patients with advanced solid ...

Spanish trade group Farmaindustria has set two objectives in biomedical research for 2025, these being consolidating Spain's ...

Swiss pharma giant Roche today announced positive top-line results from year two of the EMBARK trial, a global, randomized, ...

Privately-held Swiss biotech AB2 Bio has entered into an option and licensing agreement with Japan’s Nippon Shinyaku, which ...

Israel – a country that receives almost half of its research and development investments from foreign capital – is a striking ...

Denmark’s life sciences association, Lif, calls for a stronger political vision and regulatory reforms to advance therapies.

US pharma giant Pfizer on Saturday announced positive results from the Phase III BREAKWATER trial evaluating its Braftovi ...